Exicure (NASDAQ:XCUR) Shares Down 8.7%

Shares of Exicure, Inc. (NASDAQ:XCUR) fell 8.7% during trading on Wednesday . The stock traded as low as $0.58 and last traded at $0.58. 30,265 shares changed hands during mid-day trading, a decline of 93% from the average session volume of 412,076 shares. The stock had previously closed at $0.64.

Exicure Price Performance

The company’s fifty day moving average price is $0.62 and its 200 day moving average price is $0.61. The company has a market cap of $5.02 million, a PE ratio of 0.35 and a beta of 1.31.

Insider Activity

In other news, major shareholder Co. Ltd. Dgp sold 3,400,000 shares of the stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $1.32, for a total value of $4,488,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 8.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Exicure

A number of large investors have recently added to or reduced their stakes in the stock. UBS Group AG boosted its position in Exicure by 1,766.7% during the first quarter. UBS Group AG now owns 186,674 shares of the company’s stock worth $37,000 after purchasing an additional 176,674 shares during the period. Goldman Sachs Group Inc. boosted its position in Exicure by 329.2% during the first quarter. Goldman Sachs Group Inc. now owns 147,703 shares of the company’s stock worth $29,000 after purchasing an additional 113,293 shares during the period. Finally, Citadel Advisors LLC bought a new position in Exicure during the second quarter worth about $66,000. Hedge funds and other institutional investors own 42.82% of the company’s stock.

Exicure Company Profile

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.